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Cervical cancer is one of the more common gynecologic malignancies
diagnosedduring pregnancy; the incidence in pregnancy is estimated to
be approximately 1.6 to 10.6 per 10,000 pregnancies (Favero et al.,
2010a). Though there are well-established treatment algorithms for
the treatment of cervical cancer in non-pregnant patients, diagnosis
during pregnancy poses signiﬁcant challenges because of natural
conﬂicts between the well being of the mother and fetus. Speciﬁcally,
the issue of immediate vs. delayed deﬁnitive treatment can be a choice
between life and death for both the mother and fetus. We present
the case of a patient diagnosed with cervical cancer during the early
second trimester who underwent a robotic assisted lymphadenectomy
to assess for the presence of metastatic disease prior to a decision
regarding immediate versus delayed deﬁnitive treatment. A review of
the literature and discussion of neo-adjuvant chemotherapy as well as
surgical staging for cervical cancer diagnosed during pregnancy is also
provided.
Case study
A 32 year-old Caucasian female G4P3 presented for pre-natal care at
12 + 4 weeks gestation. A speculum exam revealed a 4 cm, exophytic
cervical mass. Her cervical cytology screening eighteen months prior⁎ Corresponding author. Fax: +1 937 222 7255.
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Open access under CC BY license.to presentation was without evidence of dysplasia or malignancy.
A bi-manual exam was notable for the absence of parametrial in-
volvement. A cervical biopsy was consistent with poorly differentiated
squamous cell carcinoma (SCC). Pelvic MRI revealed an asymmetric,
4.2 cm cervical mass without evidence of parametrial or metastatic
pelvic disease; a chest x-ray was unremarkable. Obstetric ultrasound
at 14 weeks gestation revealed normal fetal anatomy. Various treat-
ment options were offered to the patient including: (1) robotic assisted
trans-peritoneal lymphadenectomy prior to a decision regarding subse-
quent treatment, (2) Neo-adjuvant chemotherapy followed by cesarean
radical hysterectomy, (3) expectant management until fetal viability
followed by cesarean section and external beam radiotherapy with
radio-sensitizing cisplatin (chemo-EBRT), (4) immediate chemo-EBRT
or (5) radical hysterectomy with the fetus-in-situ.
The patient elected to undergo a robotic assisted transperitoneal
lymphadenectomy. A robotic assisted bilateral pelvic and para-aortic
lymphadenectomy was performed at 15 + 1 weeks of gestation.
Fig. 1 illustrates port placement of the robotic system. To facilitate
access to the right and left pelvic nodal basins, the patient was
secured to the operating table and placed in 40° lateral tilt prior
to docking each side. Intra-operative ﬁndings were notable for a
16 week sized uterus, normal fallopian tubes, ovaries, appendix and
small bowel. The resected lymph nodes were grossly normal in
appearance, and her post-operative course was uncomplicated. Final
pathology revealed a total of 25 lymph nodes with a single positive
right external iliac lymph node. The remaining lymph nodes were
negative (8 left pelvic, 12 right pelvic, and 5 para-aortic).
After extensive multi-disciplinary counseling and an institutional
ethics consultation, the patient elected for immediate deﬁnitive treat-
ment in order to maximize her survival. Planning for radiotherapy
was initiated; in anticipation of this, the patient received a single dose
of radio-sensitizing cisplatin. She subsequently declined radiotherapy
citing emotional concerns, and was then offered a type II radical
hysterectomy followed by chemo-EBRT. An uncomplicated type II
radical abdominal hysterectomy through a vertical skin incision was
performed; the patient was discharged to home on post-operative day
#3. Final uterine pathologywas notable for a 2.7 cmpoorly differentiat-
ed SCC of the cervix with deep stromal invasion, extensive lymph
vascular space invasion (LVSI) and un-involved margins. Three weeks
post-operatively chemo-EBRT was initiated. Her radiotherapy was
complicated by grade two radiation enteritis and anemia requiring
transfusion. She is disease free at 18 months from the completion of
therapy.
Fig. 1. Davinci robotic system port placement and trocar size — LUQ: 5 mm trocar for
insufﬂation and pelvic examination; 12 mm camera port 2 cm above umbilicus;
12 mm assistant port 10 cm to the right of camera port; 8 mm Davinci lateral robotic
port on the left and right side of abdomen.
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Cervical cancer is one of the few gynecologic malignancies for
which clinical staging remains the standard of care, despite well
described limitations in its ability to identify patients with asymp-
tomatic metastatic disease. This is important because the presence
of nodal disease is an extremely strong negative predictor for survival
and directs therapy from surgery to chemo-EBRT. In a retrospective
review of 401 women with stage 1B cervical cancer, Alvarez et al.
found that 5 year survival decreased from over 90% in patients
without nodal involvement to less than 70% in patients with regional
lymph node involvement (Alvarez et al., 1991).
The most challenging decision for patients and physicians faced
with a diagnosis of cervical cancer during pregnancy is whether or
not to delay deﬁnitive treatment. Two retrospective case series
(pooled n = 17) have described favorable maternal and neonatal
outcomes for clinical stage 1A disease after treatment delays
exceeding a mean of 18 weeks; all of these patients (17/17) were
without evidence of disease after a mean follow-up of 136 months
(Takushi et al., 2002; Sood et al., 1996). Based on this, it appears
that even prolonged delays in deﬁnitive treatment of patientsTable 1
Reported cases of neoadjuvant therapy followed by cesarean-radical hysterectomy for cerv
Author Year # of cases Clinical stage
at Dx
Gestational age at Dx
(weeks)
Tre
(we
Tewari 1998 1 IIA 16 18
Marana 2001 1 IIB 14 24
Palaia 2007 1 IIB 19 16
Bader 2007 1 IIA 19 14
Benhaim 2008 1 IIIB 22 6
Chun 2010 1 IIA 28 5
LN status was determined after pregnancy; Dx— diagnosis. RT— radiotherapy; Cis — cisplatin
hysterectomy; CT— chemotherapy; NED — no evidence of disease; DOD — death of disease; A
a Patient refused radical hysterectomy, lymphadenectomy and radiation treatment.with clinical stage 1A disease diagnosed during the late ﬁrst, or
early second trimester of pregnancy are unlikely to negatively affect
maternal mortality.
Patients diagnosed with stage II/III disease are much more likely to
have either clinically evident or occult metastatic disease at presentation,
and outcomes for such patients diagnosed in pregnancy are correlatively
poor. Fruscio et al. described in their literature review from 1996 to 2012
the outcomes for six stage II/III patients treated with neo-adjuvant
chemotherapy with a mean treatment delay of 14 weeks (Table 1)
(Fruscio et al., 2012). Over a mean follow-up of 28 (range 5–80) months,
3 of 6 were dead of disease and 1 was alive with disease, representing a
66% treatment failure rate (Table 1) (Fruscio et al., 2012). Conversely,
Takushi described a series of 6 patients with stage II/III disease who
were treated deﬁnitively at presentation (mean gestational age
17.5 weeks, range 6–37) (Takushi et al., 2002). Five of six of these patients
were without evidence of disease at a mean follow-up of 86 (range
4–120) months (Takushi et al., 2002). Based on these series it would be
appropriate to counsel patients that there is a signiﬁcant survival
advantage favoring immediate treatment in patients diagnosed with
stage II/III disease during pregnancy.
The prognosis for stage 1A and stage II/III in patients diagnosed
with cervical cancer during pregnancy, both with immediate and
delayed treatment, is simpler to predict than for patients with stage
1B disease. This is likely related to the fact that stages 1B1 and 1B2
patients have signiﬁcantly different node positivity rates. Among
a pooled series of patients with stage 1B cancers treated with neo-
adjuvant chemotherapy followed by cesarean delivery and deﬁnitive
therapy (n = 26) (Table 2), 1/12 (8%) of 1B1 patients and 4/14 (28%)
of 1B2 patients were found to have positive nodes at time of cesarean
hysterectomy + lymphadenectomy (Fruscio et al., 2012). Among
these 26 patients, one refused hysterectomy and lymphadenectomy
after delivery. Also, the nodal status was not available for ﬁve of the
26 patients in this series. Similarly, signiﬁcantly disparate outcomes
after neo-adjuvant chemotherapy were appreciable between stages
1B1 and 1B2 patients. In the same pooled series, 1/12 (8%) of stage
1B1 patients and 5/14 (35%) of stage 1B2 patients were dead of
disease (DOD) at a mean follow-up of 40 (27–59) months (Fruscio
et al., 2012).
Because nodal status plays such a pivotal role in determining
prognosis, particularly when considering a delay in deﬁnitive treat-
ment, several authors have described antenatal surgical staging
prior to initiating either expectant management or neo-adjuvant che-
motherapy until fetal viability. Outcomes following antenatal surgical
staging have been described for twenty-eight patients (Favero et al.,
2010a, 2010b; Alouini et al., 2008). Among women (mean age = 32)
with stage 1B disease (n = 23), 3/19 (16%) of stage 1B1 patients and
2/4 (50%) of stage 1B2 patients were found to have positive nodes
(Favero et al., 2010a, 2010b; Alouini et al., 2008). Two out of ﬁve
(40%) node positive patients, irrespective of clinical stage at diagnosis,
were DOD at a mean follow-up of 26 (range 17–36) months (Alouini
et al., 2008; Favero et al., 2010b). One of the ﬁve patients with positiveical cancer stages II–III during pregnancy: literature review (1996–2012).
atment delay
eks)
LN status at
delivery
Neoadjuvant
chemo
Treatment after
pregnancy
Mother's
outcome
Negative Cis/vinc RH/RT DOD
N/A Cis/bleo Nonea DOD
Negative Cis RH NED
Positive Cis/vinc RH/CT NED
N/A Cis RH/CT/RT DOD
Negative Carb/pac RH AD
; Pac — paclitaxel; carb— carboplatin; Vinc— vincristine; bleo— bleomycin; RH — radical
D— alive with disease; LN — lymph node; N/A — not available.
Table 2
Reported cases of neoadjuvant therapy followed by cesarean-radical hysterectomy for cervical cancer stages 1B1 and 1B2 during pregnancy: literature review (1996–2012).
Author Year # of cases Clinical stage
at Dx
Gestational
age at Dx
(weeks)
Treatment delay
(weeks)
LN status at
delivery
Neoadjuvant
chemo
Treatment after
pregnancy
Mother's
outcome
Giacalone 1996 1 1B1 17 15 Negative Cis RH NED
Lai 1997 2 1B2 N/A N/A Positive Cis/vinc/bleo RH DOD
1B2 12 N/A Negative Cis/vinc/bleo RH DOD
Tewari 1998 1 1B2 21 11 Negative Cis/vinc RH NED
Caluwaerts 2006 1 1B1 15 17 Negative Cis RH NED
Karam 2007 1 1B2 23 10 Negative Cis RH/CT/RT NED
Rabaiotti 2010 1 1B2 15 17 Positive Cis RH/CT/RT DOD
Favero 2010 5 1B1 14 19 – Cis N/A NED
1B1 18 14 – Cis N/A NED
1B1 22 14 – Cis N/A NED
1B1 14 18 – Cis N/A N/A
1B1 18 16 – Cis N/A N/A
Chun 2010 2 1B1 25 10 Negative Cis/pac RH DOD
1B2 28 8 Positive Cis/pac RH/CT NED
Smyth 2010 1 1B2 23 12 N/A Adria/CTX N/Aa NED
Li 2011 2 1B2 27 6 Negative Cis/pac RH/CT/RT NED
1B2 29 5 Negative Cis/pac RH NED
Fruscio 2012 9 1B1 22 14 Negative Cis RH NED
1B1 20 16 Negative Cis RH NED
1B1 26 10 Negative Cis RH NED
1B1 8 28 Positive Cis RH/CT/RT NED
1B2 20 15 Negative Cis RH/CT/RT DOD
1B2 16 18 Negative Cis/Pac RH NED
1B2 16 17 Negative Cis/Pac RH NED
1B2 18 14 Negative Cis RH NED
1B2 13 17 Positive Cis/vinc RH/RT DOD
LN status was determined after pregnancy; Dx — diagnosis. RT- radiotherapy; Cis — cisplatin; Pac — paclitaxel; carb — carboplatin; Vinc — vincristine; bleo — bleomycin; adria —
adriamycin; CTX — cyclophosphamide; RH — radical hysterectomy; CT — chemotherapy; NED— no evidence of disease; DOD — death of disease; AD — alive with disease; LN — lymph
node; N/A— not available.
a Radical hysterectomy and lymphadenectomy were not performed.
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2008; Favero et al., 2010b). Based on this data, antenatal surgical staging
data does provide an opportunity to reﬁne a patient's prognosis and
offer tailored guidance for those patients who are considering immedi-
ate vs. delayed treatment.
This is the ﬁrst published description of robotic assisted trans-
peritoneal lymphadenectomy for surgical staging of cervical cancer dur-
ing pregnancy. In this case, prognostic data provided by surgical staging
reﬁned prognostic counseling for this patient, informing her difﬁcult de-
cision regarding immediate vs. delayed deﬁnitive treatment in the con-
text of a desired pregnancy. While a broader discussion of clinical vs.
surgical staging for cervical cancer diagnosed during pregnancy is be-
yond the scope of this discussion, this case, and previous series describ-
ing laparoscopic surgical staging in pregnant patients have shown that
it is feasible, safe and provides signiﬁcant prognostic data to inform
patient decisions about immediate vs. delayed treatment for stage 1B
cancers. With robotic surgery becoming an increasingly utilized tool
for minimally invasive surgery, this case serves to validate its use in
pregnant patients requiring advanced laparoscopic techniques.Conﬂict of interest statement
The authors declare that there are no conﬂicts of interest.Consent
A written informed consent was obtained from the patient for
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